Arthritis and rheumatism
-
Arthritis and rheumatism · Feb 2004
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialEfficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.
To evaluate the efficacy and safety of etoricoxib and indomethacin in the treatment of patients with acute gout. ⋯ Etoricoxib at a dosage of 120 mg once daily was confirmed to be an effective treatment for acute gout. Etoricoxib was comparable in efficacy to indomethacin at a dosage of 50 mg 3 times daily, and it was generally safe and well tolerated.
-
Arthritis and rheumatism · Feb 2004
Randomized Controlled Trial Multicenter Study Clinical TrialOnce-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
To evaluate the safety, efficacy, and pharmacokinetics of 50 mg etanercept administered subcutaneously once weekly in adult patients with active rheumatoid arthritis (RA). ⋯ Safety, efficacy, and pharmacokinetics were comparable between the 2 etanercept dosing regimens. Thus, comparable clinical outcomes are to be expected when patients are treated with etanercept administered either as 50 mg once weekly or as 25 mg twice weekly.